Treatment of hyperprolactinemic amenorrhea with Metergoline.
The ergoline derivative, Metergoline, in a dosage of 4 to 24 mg/day, was administered for one to eight months to 42 patients with hyperprolactinemic amenorrhea. Mean serum prolactin (PRL) concentrations before treatment were 91.2 ng/mL in the patients with functional hyperprolactinemia (N = 29) and 256.9 ng/mL in the patients with pituitary tumor (N = 13). Within four weeks, Metergoline treatment reduced these PRL concentrations to 39.5 ng/mL and 82.9 ng/mL, respectively. In this study Metergoline treatment resulted in restoration of menstruation in a total of 37 patients; 28 patients ovulated, and eight became pregnant. It is considerably more effective in functional hyperprolactinemia than in hyperprolactinemia caused by adenoma.
D000236:Adenoma / Q000150:complications; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy* / Q000209:etiology; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology; D008711:Metergoline / Q000009:adverse effects / Q000627:therapeutic use*; D008787:Metoclopramide; D009325:Nausea / Q000139:chemically induced; D010060:Ovulation / Q000187:drug effects; D010911:Pituitary Neoplasms / Q000150:complications; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D014057:Tomography, X-Ray Computed
D004873:Ergolines; D008711:Metergoline; D011374:Progesterone; D011388:Prolactin; D008787:Metoclopramide